AVR (ASX) Ann: Successful Interim Results for the First-In-Human Trial

Originally posted by PhantomGWW: ↑

Hi all AVRers, do hope my posting come out OK--
I believe a word in the heading did not impress some and some were expecting a bigger 'fanfare' on results

Would love someone to answer my Question at foot.

The word ' interim ' - --'
the intervening time'. --'In the interim' -- 'I'll just keep my fingers crossed'
I believe if that word was excluded then maybe a better result, even with market a bit jittery. Remember the world will not end. Life will go on!!!!

Having said that I believe the report is fantastic- considering :-
-the age of the patients 'mean age 73'
-their results- I get the impression some are now in better shape than before the implant ???.
-the Doctors cannot be too expressive with their words, even though some descriptions were
extremely positive like the following :-
(you must read the report fully as I have been bias and ' picked ' out what I like)

--average 86% improvement in mean gradient (standard measure of stenosisseverity) from pre-treatment levels.
--mean gradients were up to 50% lower than other TAVR devices
--all patients are in the normal or near normal range compared to the general population with normal valve function.
--average Effective Orifice Area (EOA) up to 45% larger than those reported with other TAVR devices in matched annular sizes.2
--no conduction (heart rhythm) disturbances due to the procedure -
--no clinically significant paravalvular regurgitation despite very complex and heavily calcified anatomy.
--echocardiographic and CT imaging data showed consistent laminar flow throughout valve
--long coaptation length in all five patients. Ostensibly, indicate lower leaflet strain leading to long term durability.
--allowed for excellent commissural alignment; a significant patient benefit if future coronary intervention were required.
--making available a TAVRthat works better from the get-go and lasts longer,
-- 20% increase from baseline in 6 min walk test (a measure of patient exercise tolerance)- a 170% greater improvement
than observed in studies of other TAVR valves --a marked improvement in patients’ functional status and exercise tolerance.
--exercise performance is a critical marker of cardiac health.

--Dr. Paul Sorajja, -at Abbott Northwestern Hospital (see comment below) one of the implanting physicians “Due to its unique
leaflet design,DurAVR™continues to provide superior haemodynamics with a balloon expandable platform”.

--Dr. Vinnie Bapat, -- another member of the team - stated, “DurAVR™ rationally engineered to provide ease of implantation for the doctor,
immediate haemodynamic benefit for the patient post-implantation, potential to provide a long-term durable effect. of utmost importance
when treating younger, low-risk patients.
-- are happy to see patients on this trial doing so well with such impressive haemodynamic improvement
--"DurAVRTM continues to exceed very high expectations in a complex group of bicuspid and tricuspid patients.
The haemodynamic performance as well as valve function is remarkable.
--patients’functional status improved as did their exercise performance indicating early improvements in quality-of-life due to receiving DurAVR™
--Wayne's comments -some not all
-- '-- mimics a native aortic valve'
-- exercise performance is incredibly important and supports the use of DurAVR™ in this more active patient group who require a valve that lasts
longer and works better than current solutions.
-- represents a small No. of patients and should be viewed as such
--more results during2022,”

QUESTION - Abbott Northwestern Hospital-Remember Abbott (the one I have read about) is a big $US 230b appx Coy and from my research (read about it some time ago) is/ could be very interested in AVR's product. It is in the health industry.
I wonder is there any connection ( site map then look in -vascular-) https://www.aus.abbott/site-map.html

Expand

Hi Phantom,

Abbott Northwestern Hospital in Minneapolis is part of Minneapolis-based Allina Health and not affiliated with the Abbott you mean.

Re the report - The Doctors and company have to be a little conservative in their wording as it is only 5 patients of a 10 patient study and we need more numbers before we can get too ahead of ourselves.

However, the statistical results are what they are and scream a major success right off the page.

I would draw no conclusions from the market reaction to this report. The Ad Board were blown away by the results.

No.	Vol.	Price($)
1	3500	$6.12

No.

Vol.

Price($)

3500

$6.12

Price($)	Vol.	No.
$6.27	200	1

Price($)

Vol.

No.

$6.27

200

No.	Vol.	Price($)
1	3500	6.120
1	2000	6.100
1	1250	5.950
1	857	5.830
1	900	5.780

No.

Vol.

Price($)

3500

6.120

2000

6.100

1250

5.950

857

5.830

900

5.780

Price($)	Vol.	No.
6.300	463	1
6.400	130	1
6.500	255	1
6.550	1092	1
6.600	320	1

Price($)

Vol.

No.

6.300

463

6.400

130

6.500

255

6.550

1092

6.600

320

(20min delay)
Last $6.27		Change 0.360(6.09%)		Mkt cap ! $97.17M

Open	High	Low	Value	Volume
$5.93	$6.30	$5.91	$107.9K	17.39K

Hi Phantom,Abbott Northwestern Hospital in Minneapolis is part...

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Monash IVF shares cater 25% – Disaster or deep-value play?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Hi Phantom,Abbott Northwestern Hospital in Minneapolis is part...

Top Stories

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Monash IVF shares cater 25% – Disaster or deep-value play?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News